LQDA 144 SEC Filing Analysis

Latest settled — T+20d ⚠ clustered

LQDA ▲ +51.27% at T+20d

SHORT call ✗ call lost -51.27% · α vs SPY -47.07% · entry $37.66 → $56.97

Next anchor: T+60d in 5w

Last close $63.90 (close Jun 8) · -69.68% from $37.66 entry (call sign-flipped)

Entry anchored
Apr 17, 03:59 PM ET
via Databento tick

T+1d

-3.74%

call +3.74% · α +3.09%

$36.25

settled 7w ago

T+5d

-0.85%

call +0.85% · α +1.76%

$37.34

settled 7w ago

T+20d

+51.27%

call -51.27% · α -47.07%

$56.97

settled 26d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Roger Jeffs, a director and officer of Liquidia Corp, filed a Form 144 to report proposed sales of 148,277 shares through Serendipity Biopharma LLC and personal transactions, with recent sales totaling approximately $4.0 million over five days in mid-April 2026. The sales are conducted under a 10b5-1 plan, indicating prearranged trading, but come amid elevated insider selling activity.

Actionable Insight

Traders should monitor for continued insider selling, especially given the 10b5-1 plan execution and recent volume. While prearranged, the scale and timing—amid a $3.6B market cap—may signal reduced confidence, particularly if not offset by fundamentals in upcoming earnings.

Key Facts

Roger Jeffs, Director and Officer of Liquidia Corp, is the reporting owner.
Form 144 filed for 148,277 common shares, with recent sales executed between April 9–17, 2026.
Total value of reported transactions: ~$4.01 million (sum of $1,007,800 + $1,003,522.50 + $132,000 + $1,256,387.28 + $859,876.96 + $1,002,887.50).
Sales conducted under a 10b5-1 plan for Serendipity Biopharma LLC, suggesting pre-planned disposition.
Recent insider activity shows 6 sell transactions in the past 30 days totaling $3.9M, indicating sustained insider selling pressure.

Financial Impact

$4.01 million in proposed and recently executed sales by a corporate insider

insider ownershipmarket sentimentpotential dilution perception

Risk Factors

Perception of insider pessimism despite 10b5-1 plan justification
Increased selling pressure from affiliates could weigh on share price
Lack of offsetting insider buying or positive corporate news

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

Document	Accession Number
144 Filing (Primary)	0001950047-26-003618
Document: 0001950047-26-003618-index.html	0001950047-26-003618
Document: 0001950047-26-003618.txt	0001950047-26-003618

30 reports for LQDA

T+1T+5T+20T+60

80% Hit rate 8 of 10 directional calls best @ T+60▲ +70.18%Mar 5, 2026

Filters

Reports for LQDA — sortable, filterable
	Type				Now
Jun 8, 2026 1d ago	Insider Cluster NEUTRAL ★ 3/10	$63.94 awaiting T+1	awaiting T+1	—	$63.90 (−0.06%)
Jun 8, 2026 1d ago	CLUSTER / 8-K NEUTRAL ★ 5/10	$63.94 awaiting T+1	awaiting T+1	—	$63.90 (−0.06%)
Jun 4, 2026 5d ago	144 BEARISH ★ 6/10	$62.76 awaiting T+1	awaiting T+1	—	$63.90 (−1.82%)
Jun 4, 2026 5d ago	144 BEARISH ★ 5/10	$62.76 awaiting T+1	awaiting T+1	—	$63.90 (−1.82%)
Jun 3, 2026 6d ago	Insider Cluster NEUTRAL ★ 3/10	$62.54 $61.85	▼ −1.10%	▲ +1.50%	$63.90 (+2.17%)
Jun 1, 2026 8d ago	144 NEUTRAL ★ 4/10	$58.75 $55.11	▼ −6.20%	▼ −6.34%	$63.90 (+8.77%)
May 26, 2026 14d ago	Insider Cluster NEUTRAL ★ 4/10	$62.03 $62.03	· 0.00%	▼ −0.55%	$63.90 (+3.01%)
May 21, 2026 20d ago	Insider Cluster MIXED ★ 5/10	$61.97 $60.98	▼ −1.60%	▼ −2.04%	$63.90 (+3.11%)
May 20, 2026 20d ago	Insider Cluster NEUTRAL ★ 4/10	$61.97 $60.98	▼ −1.60%	▼ −2.04%	$63.90 (+3.11%)
May 15, 2026 25d ago	Insider Cluster NEUTRAL ★ 3/10	$56.97 $59.98	▲ +5.28%	▲ +5.93%	$63.90 (+12.16%)

US Market Status

Market Closed — Opens in 8h 32m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access